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Abstract 
Introduction: Product switching followed by suspected adverse events are common and unsettling for antiepileptic drugs. The objective 
of this case study was to describe the investigation performed after report of suspected therapeutic failure in pediatric patients 
following a switch to a different valproate manufacturer and identify strategies concerning medication management for improving 
therapeutic outcomes. Case description: It was reported that different pediatric patients’ condition changed (agitation/ seizures) after 
refilling the same drug prescription (sodium valproate syrup) from a different manufacturer. Medical staff reported a suspected 
therapeutic failure and some units of the product batch associated with the problem were seized by the local Post-marketing 
Surveillance Service for investigation of potential quality deviations. The seized units were evaluated by the State’s Surveillance 
Laboratory, nevertheless, drug potency was found to be 98.7%. Conclusion: We consider that the reported event could be associated 
with aspects of medication use, i.e. potential dose measurement deviations resulting from remaining of residual liquid in the cup or 
eventual delay at prescription refilling process and consequential - even though brief - pharmacotherapy discontinuity. Patient 
education and counseling by pharmacists are essential for preventing drug-related problems and enhancing positive outcomes of 
pharmacotherapy.  
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Introduction 
Liquid medications facilitate drug administration for pediatric 
patients and allow dose adjustment1 - an essential part of 
neuropsychiatric drugs management. Nevertheless, measuring 
devices used for drug delivery are associated with a potential 
risk of under or overdosing,2 which is particularly critical for 
narrow therapeutic index (NTI) drugs such as valproate. 
 
Antiepileptic drugs (AED) switching is referred to the change 
from one product to another of the same drug, i.e., brand to 
generic, generic to brand, or generic to generic AED products 
from different manufacturers.3,4 
 
Some studies have speculated that small variations in 
bioavailability between products - including those within the 
standard bioequivalence range - could result in adverse clinical 
outcomes when patients switch between manufacturers of a 
NTI drug, such as AED.5 
 
Concern over this topic is supported by reports of product 
switching followed by suspected adverse events, which are 
particularly common for AED and have been extensively 
discussed because of their unexpected clinical outcomes such 
as loss of seizure control, increased seizure frequency, 
occurrence of adverse drug effects, hospitalization and higher 
healthcare services use.3-6 
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Different observational studies have been conducted to identify 
potential links between AED switching and seizure related 
events, however, most of the studies were subject to bias and 
general results were conflicting.7,8 
 
The objective of this case study was to describe the 
investigation performed after report of suspected therapeutic 
failure in pediatric patients following a switch to a different 
valproate manufacturer and identify strategies concerning 
medication management for improving therapeutic outcomes. 
 
Case description 
The mother of a pediatric patient under treatment in a 
specialties public outpatient facility noted that her son’s 
condition changed after refilling the same drug prescription - 
250mg/5mL sodium valproate syrup packaged in plastic bottles 
with accompanying dosing cup - from a different manufacturer. 
Doses were measured with the dosing cup packaged with the 
medication. Investigation pointed that other patients’ mothers 
from the same outpatient facility also noticed that their children 
became agitated or even had seizures after switching between 
the products. Each patient was put on the same two 
manufacturers of valproate syrup in the same sequence, as 
medication was dispensed by the outpatient facility 
systematically. No information regarding dose changing or any 
other factor that could have influenced patients’ condition was 
reported. Accordingly, medical staff reported a suspected 
therapeutic failure. 
 
Some units of the product batch associated with the problem 
were seized by the local Post-marketing Surveillance Service for 
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investigation. The seized units were evaluated by the State’s 
Surveillance Laboratory. Potential deviations in drug potency 
were evaluated using a HPLC-DAD system (Waters, Milford, 
USA) at the following conditions: C8 column (4.0 x 250mm, 
5µm, Agilent, Santa Clara, USA), flow rate of 1mL/min, injection 
volume of 20µL and detection set at 215nm. Mobile phase 
consisted of monobasic sodium phosphate buffer solution 
(Vetec/Sigma-Aldrich, Duque de Caxias, Brazil) and acetonitrile 
(Merck, Darmstadt, Germany). Valproic acid reference standard 
(USP, Rockville, USA) was used for quantitation of the sample. 
The amount of sodium valproate was expressed as valproic 
acid.9 
 
Results showed that the product contained 98.7% of the labeled 
amount of valproic acid (specification: 90-110%9). The amount 
of drug in individual doses could not be checked as there is no 
pharmacopeial test for dose delivery using dosing cups. 
 
Discussion 
As a NTI drug, a small variation in valproate dose might result in 
serious therapeutic failure or adverse reactions.10 Also, 
pediatric patients usually require a weight-based dosing 
strategy, thus a small variation in the measured dose may also 
have clinical implications,11 requiring increased attention. 
 
The laboratory analysis performed on the seized units showed 
that the reported suspected therapeutic failure was not 
associated with any deviation in drug product potency. Thus, we 
discuss three different hypotheses regarding the medication for 
elucidating the case: 
 
A. Inaccurate measurement of doses 
High rates of inaccuracy in doses measured with dosing cups 
have been reported previously.1,12,13  Sobhani et al, 2008 found 
that only 14.6% of participants measured an acceptable dose 
(±10% of the requested volume) of 5mL of acetaminophen 
suspension when using the cup, with a measured mean volume 
of 6.3±0.7mL. Only 4.2% of the participants measured an 
accurate dose (5mL) when using the cup. Also, they were five 
times less likely to measure acceptable doses when using the 
cup versus the dosing syringe.13 
 
Caregivers of a minor patient who has been taking sodium 
valproate syrup for a long time are expected to measure the 
prescribed doses accurately. Nevertheless, dosing cups 
potentially retain residual liquid after dose administration, 
especially when measuring viscous formulations.14 Supposing 
that the refilled new formulation was significantly more viscous 
than the original one, a potential unobserved remaining of 
residual liquid in the cup would result in the delivery of 
underdoses with consequent clinical outcomes. 
 
Abu-Geras et al, 2016 found that accuracy decreased for cup 
measurements when viscosity of the liquid increased. In 
contrast, the measurement of higher viscosity liquids was more 
accurate when using a dosing syringe.15 
B. Variability between manufacturers of the same drug 
The standard bioequivalence range of 80-125% has been 
pointed by some as too broad to avoid clinical differences in 
bioavailability between different products, especially for NTI 
drugs, such as AED.7 
 
It has been suggested that AED bioequivalence may not 
demonstrate therapeutic equivalence between products, i.e., 
variability within accepted limits would still compromise seizure 
control.4 
 
Theoretically, the difference between two generic products 
would be even greater, as they could fall at extremes of the 
brand product’s bioequivalence range.7,16 
In 2016, the American Epilepsy Society stated that substitution 
with generic products approved by the FDA reduces treatment 
costs and does not compromise its efficacy.16,17 Indeed, generic 
drugs have been associated with better adherence than their 
corresponding brand products due to low costs. Enhancing 
patient adherence is essential for treatment with AED, 
considering that greater medication adherence contributes for 
achieving and maintaining effective blood levels and 
consequently results in better clinical outcomes.7 
 
Nevertheless, adverse outcomes associated with AED switching 
still concern patients and clinicians. Indeed, some authors 
recommend that whenever possible patients should be kept on 
a single AED manufacturer to avoid product switching.8,18 
 
Conversely - because of the dosage form - drug release from the 
drug product is assumed to be self-evident for syrups and other 
solubilized forms. Accordingly, if the drug product also contains 
the active ingredient in the same concentration and dosage 
form as the reference listed drug and does not contain 
excipients or changes in formulation that significantly affects 
drug absorption or availability, in vivo bioavailability data can be 
waived.19-21 
 
Considering that valproate products were given as syrup, it is 
unlikely that the suspected therapeutic failure reported in this 
case was associated with any bioavailability differences 
between manufacturers. 
 
C. Delay in refilling or variation in drug use pattern 
Association between interchangeability and seizure events 
might result to some extent from delay in refilling, lack of 
information about the medication, difficulties in managing a 
complex therapeutic regimen, temporary treatment non-
adherence or small alteration in the medication use pattern.5 
 
Some studies pointed that prescription refilling itself - even 
when involving the same medicine from the same manufacturer 
at the same strength - was associated with an elevated risk of 
seizure-related events.5,16 
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Patients were switched among different manufacturers because 
the facility’s pharmacy changed its supply source. An eventual 
delay during restocking would potentially have uncovered 
refilling process and might then be identified as the common 
cause for the reported event, as therapeutic failure was 
reported during the exact same period for more than one 
patient. 
 
Investigation was focused on aspects regarding the product as 
Post-marketing Surveillance Service initially suspected that the 
reported event was a result of quality deviation in the potency 
of the medication. However, potency was proven to be within 
the acceptable limits after laboratory tests and this matter was 
discarded. 
 
Limitations of this investigation include that specific details 
related to the case (patients’ medical and refill records, serum 
concentrations of the drug, investigation of poor/ fast 
metabolizers and exact number of patients) were not described 
in the report form that went with the seized product. Also, we 
could not compare viscosity measurements as the original 
formulation used by the patients was not seized for laboratory 
tests. 
 
It is crucial to implement and continue operating functional 
prescription refilling systems. Even when facing an eventual 
manufacturer switching during the medication purchase 
process, prescription refilling should not be uncovered, 
especially for neuropsychiatric drugs and others which demand 
continuous use. 
 
Patients might be assisted for selecting the best device for 
measuring the liquid medication according to their needs, 
considering product’s own characteristics. Using a dosing 
syringe instead of a cup might be more appropriate for 
measuring doses of viscous formulations containing NTI drugs. 
 
The management of the prescribed therapeutic regimen should 
be reinforced by pharmacists in order to avoid patients skipping 
doses or changing medication use instructions, e.g. timing, 
dosing and duration of treatment, which potentially would 
affect its efficacy. 
 
Indeed, it has been suggested that alteration in medication use 
pattern is just as important as pharmacokinetics regarding 
variation in clinical response.5 
 
Conclusion 
Aspects of medication use may have contributed for the 
assumed association between manufacturer switching and loss 
of seizure control in pediatric patients. We consider that the 
reported therapeutic failure could be associated with potential 
dose measurement deviations resulting from remaining of 
residual liquid in the cup or eventual delay at prescription 
refilling process and consequential - even though brief - 
pharmacotherapy discontinuity. 
Further investigations regarding caregivers’ ability to measure 
prescribed doses accurately are needed. Also, different aspects 
of AED switching still need to be investigated, as findings remain 
conflicting. 
 
We recommend the use of a dosing syringe instead of a dosing 
cup for dose measurements of critical drugs, such as valproate. 
Still, we suggest that other factors such as medication 
adherence and variation in drug use pattern be considered 
when investigating associations between AED switching and 
reduced clinical response. 
 
Patient education and counseling by pharmacists are essential 
for preventing drug-related problems and enhancing positive 
outcomes of pharmacotherapy. 
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